Kornimate/medical-research-clean huggingface dataset:
characteristics of pain in women with lipoedema

Conditions: Lipedema

Summary: this observational study will seek to investigate the following questions in women with lipoedema: * pain characteristics, intensity and patterns of pain * the relationships between the characteristics, intensity and patterns of pain and age, ethnicity, location, employment status, levels of anxiety/depression, walking ability, ability to work, relations with other people, impact on sleep and quality of life. * the impact of pain treatments or medications on the intensity of pain. the information will be collected via an online survey and participants will be recruited through social media platforms.

lipoedema is a chronic adipose tissue disorder that occurs almost exclusively in women and affects approximately 11% worldwide. pain is a recurring feature described by people with lipoedema (pwl) with a recent study reporting 88.3% of patients indicating pain as a clinical feature. it has been suggested, with chronic long-term conditions, that the pain people experience can be moulded by a myriad of elements.this includes biomedical, psychosocial (e.g. patients' beliefs, expectations, and mood), and behavioural factors (e.g. context, responses by significant others). pwl often experience significant impairment in their daily activities and quality of life. it has further been found that psychological and the biomedical consequences of lipoedema can increase the chances of anxiety and depression which can subsequently further impact on quality of life and pain experience. this observational study will seek to investigate the following questions in women with lipoedema: * pain characteristics, intensity and patterns of pain * the relationships between the characteristics, intensity and patterns of pain and age, ethnicity, location, employment status, levels of anxiety/depression, walking ability, ability to work, relations with other people, impact on sleep and quality of life. * the impact of pain treatments or medications on the intensity of pain. information about pain characteristics, demographics, mood, functional ability and quality of life will be collected via an online survey and participants will be recruited through social media platforms.

Eligibility criteria:
inclusion criteria: * women with lipoedema * 16 years and older exclusion criteria: - inability to provide consent

Keywords: pain emotional status quality of life
evaluation of severity in juvenile and adult-onset dermatomyositis

Conditions: Dermatomyositis

Summary: dermatomyositis (dm) are rare and heterogeneous systemic autoimmune diseases, characterized by the association of muscle inflammation, skin inflammation and vasculopathy. dm concern both adults and children. dm can be life-threatening (interstitial lung disease, infectious complications) and responsible of significant functional disability (muscle weakness). age of onset appear to be an independent prognostic factor. juvenile-onset dm is characterized by a higher frequency of calcinosis, skin ulceration and digestive vasculitis. in adults, interstitial lung disease and cancer are more frequent with higher mortality. data concerning the comparison of the initial severity between juvenile and adult-onset dm are limited. the main objective is to compare global severity between juvenile dm and adult-onset dm at initial diagnosis. secondary objectives are: * to compare organ-specific severity between juvenile dm and adult-onset dm at diagnosis. * to compare damage during follow-up and at last follow-up between juvenile dm and adult-onset dm. * to compare activity at the last follow-up between juvenile dm and adult-onset dm. * to compare iatrogenic complications between juvenile dm and adult-onset dm.


Eligibility criteria:
inclusion criteria: * patient with dermatomyositis according to 2017 american college of rheumatology (acr)/ european alliance of associations for rheumatology (eular) classification exclusion criteria: * patient with cancer-associated dermatomyositis (within 3 years before or after diagnosis of dermatomyositis) * patient with antisynthetase syndrome
quality control of colposcopy application

Conditions: Cervical Cancers; Cervical Intraepithelial Neoplasia (CIN)

Summary: colposcopy has become an important link and tool in the prevention and treatment of cervical cancer. the quality and pathological assessment of colposcopy is a key point in follow-up and treatment.the main purpose of this study was to analyze the correlation between colposcopy indications and pathological findings.

1. inclusion/exclusion criteria inclusion：(1) at least 18 years of age; (2) complete colposcopy report; (3) clear pathological diagnosis was reported after colposcopic biopsy. exclusion：not all of the above criteria are met 2. study purpose main purpose 1）analyze the correlation between colposcopy indications and pathological findings secondary purpose 1. influence of colposcopic transformation area type on pathological evaluation 2. colposcopic follow-up results 3. the differences and causes of colposcopic biopsy pathology and histology 4. quality of colposcopy in our hospital （3）retrospective study data of out-patient population in our hospital from 2005 were included

Eligibility criteria:
inclusion criteria: 1. at least 18 years of age; 2. complete colposcopy report; 3. clear pathological diagnosis was reported after colposcopic biopsy. exclusion criteria: 1. under 18 years of age; 2. lack of colposcopic reports; 3. lack of cervical biopsy pathology results; 4. other conditions deemed inappropriate by the investigator to participate in this study.

Keywords: cervical cancers cervical intraepithelial neoplasia
external validation of the clinical pre-hospital "red- flag" alert for activation of intra-hospital hemorrhage control response in blunt trauma.

Conditions: Trauma Injury

Summary: external validation of the clinical pre-hospital "red- flag" alert for activation of intra-hospital hemorrhage control response in blunt trauma.

severe trauma, with a variety of causes, is responsible for more than 9% of the world's population and is the leading cause of preventable mortality among 15-35 year olds. massive hemorrhage remains the second leading cause of early mortality in those traumatized after head trauma, accounting for about 40% of deaths. in 71% of cases this mortality is pre-hospital without access to rapid medicalization. intra-hospital mortality is also important. the main factors explaining this mortality in patients with severe bleeding are delays in recognition and management. the effectiveness of the "trauma systems" and the management channels for severe traumatized injuries are thus generally assessed by the intra-hospital mortality rate. optimal and early management is therefore essential from the pre-hospital phase. the treatment of traumatic hemorrhagic shock requires means of local hemostasis, medication management and can go as far as the establishment of massive transfusion protocols (ptm). this type of ptm is activated in about 8% of cases. while it is little practiced in pre-hospital and still debated today, its early hospital establishment is essential. rym hamada et al. highlighted a predictive score "red-flag" of severe hemorrhage in severe traumatized patients requiring the immediate implementation of rapid hemorrhage control (activation of ptm, hemostasis surgery, etc.). this score is based on 5 clinico-biological items. a score of 2 or more is predictive of an immediate intra-hospital action of hemostasis. in france, several networks are organized around centers 15 and hospitals specialized in the management of severe traumatized, from alert to definitive treatment, in accordance with the international recommendations in force. the objective of this study is to perform external and prospective validation, within a new cohort, of the "red-flags" score. for this, we are conducting a multicenter and prospective study

Eligibility criteria:
inclusion criteria: * adult patients (more than 18 yo) * regulated by the medical regulation centers (samu - centres 15) of the hospitals of angers (samu 49), rennes (samu 35), le mans (samu 72), tours (samu 37), laval (samu 53) and chambéry (samu 73) * patients with severe trauma classified as a or b * and benefiting respectively from hospital support in trauma centers * not subject to limitation of active therapeutics * member or beneficiary of a social security scheme exclusion criteria: * patients with not considered severe trauma (not a, b or c) after pre-hospital medical assessment * patient objecting to participating in research

Keywords: injury severe haemorrhage severe trauma
exercise training after transcatheter aortic valve implantation

Conditions: Aortic Valve Stenosis; TAVI; Transcatheter Aortic Valve Implantation; Rehabilitation

Summary: in this prospective, controlled trial, patient after tavi will be randomized to either exercise training or usual care group.

patients after transcatheter aortic valve replacement (tavi) are particularly old and severely deconditioned and are thus likely to benefit from cardiac rehabilitation programs. in this controlled trial, patients after tavi will be randomized to either exercise training or usual care. the aim of our study is to compare the effect of exercise training vs. usual care on: 1. exercise capacity 2. vascular function 3. parameters of heart failure, inflammation and homeostasis 4. arrhythmogenic potential 5. health-related quality of life

Eligibility criteria:
inclusion criteria: * tavi procedure 3-6 months prior to inclusion, * movability (100 meters or more on 6-minute walking test after tavi), * ability to attend a 12 week exercise training program, * physical and clinical ability to attend the rehabilitation program at the discretion of the researcher, * optimal medical treatment, * pre-signed statement of a conscious and free consent to the inclusion in the clinical trial. exclusion criteria: * contraindications for exercise training, * unstable hearth (uncontrollable heart failure - new york heart association stage iv, dysrhythmias, uncontrollable myocardial ischemia), * patient's decision to undergo tavi despite receiving a recommendation for surgical aortic valve repair by the heart team, * non-cardiac physical impairment that would prevent exercise training on stationary bike, * uncontrolled pulmonary disease (fev1 \<50%), * echocardiographic signs of prosthesis dysfunction according to the valve academic research consortium (valve orifice area of b1.2 cm2 plus a mean transaortic pressure gradient of ≥20 mm hg, or a velocity of ≥3 m/s, at least moderate paravalvular regurgitation), * tavi access site complication, * important peripheral vascular disease, musculoskeletal disease or central nervous system disease, which prevents exercise training on stationary bike, * recent (less than 3 months) acute events or illnesses that are contraindications for exercise training.

Keywords: exercise training
a comparison of visual function after bilateral implantation of presbyopia-correcting intraocular lenses (iols)

Conditions: Cataract

Summary: the purpose of this study is to evaluate visual and refractive parameters in a series of subjects bilaterally implanted with presbyopia-correcting intraocular lenses (iols) during cataract surgery.

each subject completed a preoperative examination of both eyes, implantation of iol at the operative visit for each eye, and up to 4 postoperative visits (each eye examined at day 1-2, with binocular visits at month 1 and month 3 after the second implantation). the second implantation occurred within 30 days of the first.

Eligibility criteria:
inclusion criteria: * sign informed consent; * able to attend postoperative examinations per protocol schedule; * diagnosed with bilateral cataracts; * planned cataract removal by phacoemulsification with implantation of an intraocular lens (iol); * preoperative astigmatism ≤ 2.5 diopter; * good ocular health, with the exception of cataracts; * free of disease(s)/condition(s) listed in the "caution" section of the acrysof iq and acri.lisa package inserts; * able to undergo second eye surgery within one month of the first eye surgery; * other protocol-defined inclusion criteria may apply. exclusion criteria: * previous corneal surgery; * planned multiple procedures during cataract/iol implantation surgery; * any ocular disease and/or condition that may compromise study results; * pregnant or planning pregnancy during course of study; * history of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.) * diabetic retinopathy; * macular degeneration; * history of retinal detachment; * other protocol-defined exclusion criteria may apply.

Keywords: intraocular lens presbyopia multifocal
study to evaluate the safety and effectiveness of the codman enterprise® vascular reconstruction device

Conditions: Intracranial Aneurysm

Summary: the purpose of this study is to demonstrate effectiveness and safety of the codman enterprise® vascular reconstruction device and delivery system.

the study is a prospective, multi-center, single arm, clinical study to evaluate the safety and effectiveness of the enterprise stent when used in conjunction with endovascular coil embolization in the treatment of unruptured wide-neck, intracranial, saccular anterior circulation aneurysms (≤ 10 mm). the primary objectives of the study are to evaluate the rate of complete angiographic occlusion at 12 months.

Eligibility criteria:
inclusion criteria: * target aneurysm is an unruptured wide-neck, intracranial, saccular anterior circulation aneurysm (≤ 10 mm) arising from a parent vessel with a diameter of ≥ 2.5 mm and ≤ 4 mm * subject understands the nature of the procedure and provides voluntary written informed consent prior to the treatment * subject is willing to comply with specified follow-up evaluation exclusion criteria: * planned staged procedure * currently enrolled in another investigational device or drug study * target aneurysm that has been previously treated * mycotic, fusiform or dissecting aneurysm * admission platelet \ 3.0 * a serum creatinine level \> 2.5 mg/dl within 7 days prior to index procedure

Keywords: codman enterprise® vascular reconstruction device wide neck, intracranial, saccular aneurysms cerebral aneurysms
a study to assess symptom burden in subjects with nonmyeloid malignancies receiving chemotherapy and aranesp®

Conditions: Anemia

Summary: the purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving chemotherapy supported with aranesp®.


Eligibility criteria:
inclusion criteria: * subjects with nonmyeloid malignancy(ies) * anemia (hgb less than or equal to 11.0 g/dl) due to cancer and chemotherapy exclusion criteria: * subjects with acute myelogenous leukemia (aml), chronic myelogenous leukemia (cml), myelodysplastic syndromes (mds) * unstable cardiac disease or anemia due to other causes

Keywords: chemotherapy induced anemia amgen aranesp® darbepoetin alfa
subclinical cardiovascular disease in psoriatic disease

Conditions: Cardiovascular Diseases; Myocardial Infarction; Atherosclerotic Cardiovascular Disease; Thrombotic Vascular Disease

Summary: this study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this cvd risk. the aim of this study is to 1) evaluate the association between moderate to severe psoriatic disease and measures of vascular function. 2) evaluate the association between moderate to severe psoriatic disease and measures of thrombotic risk. 3) understand how traditional medications used in cardiovascular disease (cvd) prevention such as aspirin and statins affect vascular function and thrombotic risk in those with moderate to severe psoriatic disease.

cardiovascular disease (cvd) remains the leading cause of death in the us. five modifiable risk factors: smoking, hyperlipidemia, diabetes, hypertension and obesity, account for 50% of cvd mortality between the ages of 45 - 79.1 these traditional cardiac risk factors dictate who to treat with primary prevention measures but do not take into account patient-specific disease states such as psoriatic disease including psoriasis and psoriatic arthritis, which predispose to chronic inflammation. patients with psoriatic disease have an increased risk of atherosclerotic heart disease and myocardial infarctions compared to matched controls.

Eligibility criteria:
inclusion criteria: * subjects with a history of moderate to severe psoriatic disease * group 2: healthy subjects without known psoriatic disease or cardiovascular disease exclusion criteria: * unable to speak spanish or english * active smoking (within the past year) * autoimmune, rheumatologic or inflammatory disease which are not psoriasis or psoriatic arthritis * known active cancer receiving treatment * pregnancy * anemia (hemoglobin \ 600) * a history of severe bleeding or bleeding disorders * current medication use which interact with either aspirin or atorvastatin * chronic kidney disease (crcl \< 30ml/min) * congestive heart failure * currently taking aspirin or a statin. * nsaid use within the past 48 hours

Keywords: cardiovascular disease cvd
improving cardiovascular health in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: researchers have found a link between chronic obstructive pulmonary disease (copd) and heart disease; however, a link is all they have found. cardiovascular health in copd is controlled by different mechanisms including vascular health and systemic inflammation. the investigators have collected preliminary data to support that concentrations of sirtuin 1 (sirt1), a protein that plays a key role in cardioprotection, may be involved in cardiovascular health in patients with copd. resveratrol, an over the counter natural polyphenol found in a variety of food, is a direct activator of sirt1 and has been used to improve cardiovascular health in different cohorts. the current project is an attempt to expand previous findings and explore the effects of the sub-chronic use of resveratrol in sustaining the improvements in cardiovascular health in copd.

the present study is designed as a double-blind, randomized, cross-over, placebo-controlled protocol. patients with copd will receive either resveratrol (500 mg) or placebo for 12 weeks. a comprehensive evaluation of cardiovascular health will be performed. results will provide novel insights into the mechanistic role that sirt1 mediates in copd related vascular dysfunction and systemic inflammation.

Eligibility criteria:
inclusion criteria: * participants with a clinical diagnosis of copd known for at least one year will be allowed to participate * global initiative for chronic obstructive lung disease (gold) stages ii to iv * breathing test ratio (fev1/fvc) \<0.7 * amount of exhaled air (fev1) \<80% predicted after bronchodilator * total lung capacity (tlc)\>80% * matched healthy volunteers without copd. exclusion criteria: * fev1/fvc\>0.7 * clinical diagnosis of heart disease, hypertension or diabetes * use of vasoactive medications (nitrates, beta blockers) * uncontrolled high blood pressure * pulmonary hypertension * fluid in the lungs * sleep apnea * thyroid problems * anemia * raynaud's phenomenon * gastrointestinal bleeding * history of coagulopathies * history of low platelets * gangrene of the digits * phenylketonuria * pregnant or women attempting to become pregnant * in lactation * individuals who may not be able to read or understand the resveratrol label

Keywords: copd
statistical learning as a novel intervention for cortical blindness

Conditions: Stroke, Ischemic; Hemianopia, Homonymous; Hemianopsia; Occipital Lobe Infarct; Visual Field Defect, Peripheral; Vision Loss Partial; Quadrantanopia; Stroke Hemorrhagic

Summary: this project aims to develop a novel visual training paradigm for use in visually-intact participants and those sufferings from stroke-induced visual impairments. our task design is built upon theories of statistical learning to reduce the overall training burden while still producing profound improvements to visual abilities. efficacy will be first established in visually-intact controls before testing in stroke survivors to assess the feasibility of this form of learning in the damaged visual system.


Eligibility criteria:
cortically blind participants inclusion criteria: * between 21 and 75 years of age * residents of the united states or canada * have successfully completed previous enrollment in dr. huxlin study (irb #5966 or #75) * exhibit unilateral stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained within the specified age range of 21 - 75 years (verified by mri and/or ct scans) * reliable visual field defects in both eyes (homonymous defects) as measured by humphrey visual fields. this deficit must be large enough to enclose a 5-deg diameter visual stimulus. * able to fixate on visual targets reliably for 1000ms within 1-deg of visual angle. * willing, able, and competent to provide their own informed consent * normal cognitive abilities and be able to understand written and oral instructions in english exclusion criteria: * past or present ocular disease interfering with visual acuity * best corrected visual acuity (bcva) worse than 20/40 in either eye * sustained documented or suspected damage to the dorsal lateral geniculate nucleus * presence of diffuse whole brain degenerative processes * history of traumatic brain injury * any other brain damage deemed by study staff to potentially interfere with training ability or outcome measures * documented history of drug/alcohol abuse * currently taking neuroactive medications which would impact training, as determined by pi * cognitive or seizure disorders * one-sided attentional neglect * those who lack the competence or are otherwise unable to perform the visual training exercises as directed. control participants inclusion criteria: * between 21 and 75 years of age * no history of neurological disorder. * competent and responsible, as determined by the screening interview exclusion criteria: * any damage to the visual system * those who are suffering from an active disease process involving their nervous system. * presence of cognitive or seizure disorders * best corrected visual acuity worse than 20/40 in either eye * presence of visual field loss from ocular disease or disorder

Keywords: occipital stroke vision loss after stroke vision recovery vision restoration partial vision loss